Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 24;8(24):6334-6336.
doi: 10.1182/bloodadvances.2024015305.

Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances

Catherine M Bollard, Andrew S Weyrich

Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances

Catherine M Bollard et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: For Wistinghausen et al, C.M.B. is a cofounder and scientific advisory board member of Mana Therapeutics and Catamaran Bio; board member of Cabaletta Bio; has stock in NexImmune and Repertoire Immune Medicines; serves as a data safety monitoring board member for Sobi; and has served on advisory boards for Pfizer, Bristol Myers Squibb, and Roche. A.S.W. declares no competing financial interests.

Similar articles

See all similar articles

References

    1. Haydu JE, Abramson JS. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Adv. 2024;8(17):4700–4710. - PMC - PubMed
    1. Perna F, Parekh S, Diorio C, et al. CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations. Blood Adv. 2024;8(16):4348–4358. - PMC - PubMed
    1. Baguet C, Larghero J, Mebarki M. Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies. Blood Adv. 2024;8(2):337–342. - PMC - PubMed
    1. Reynolds G, Cliff ERS, Mohyuddin GR, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7(19):5898–5903. - PMC - PubMed
    1. Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023;7(20):6266–6274. - PMC - PubMed